The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists in over 100 countries.
IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.
The IASLC mission is:
- to embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies;
- to provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public;
- to use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.
The Journal of Thoracic Oncology
The Journal of Thoracic Oncology (JTO) is the IASLC's premier Journal. JTO emphasizes a multidisciplinary approach in the articles accepted for publication, and includes original research (clinical trials and translational or basic research), reviews and opinion pieces. Become a member of IASLC and receive a complimentary subscription to the Journal of Thoracic Oncology. Members can login to the IASLC Member Portal to access the Journal articles (Membership must be current.)
The core audience for the Journal includes those involved in the research and treatment of thoracic malignancies including, epidemiologists, medical oncologists, pulmonologists, radiation oncologists, thoracic surgeons, radiologists, pathologists and research scientists.
First published in January of 2006, the journal is a monthly publication. The 2016 Impact Factor was 6.595, up from 5.040 in 2015. This increase in Impact Factor is a clear indicator of the journal’s commitment to publishing high quality research that is integral to the field of thoracic oncology. The JTO is ranked 23 out of 217 for oncology and 6 out of 589 for respiratory system subject matter categories in the 2016 Journal Citation Reports. In 2016, 994 original research articles were submitted with acceptance of 168, resulting in an acceptance rate of 16.9%. For all submission types, there were 1441 manuscripts submitted and 247 were accepted, equating an acceptance rate of 17.1%. The journal has a quick turn-around time of 6.7 days to initial decision, and an average of 11 days for revisions, a fast track category, publish on acceptance and promotion of select articles via social media and press releases.
Meet the Editor
Alex A. Adjei, MD, PhD, FACP
Dr. Adjei is Professor of Oncology in the Department of Medicine at Mayo Clinic in Rochester, Minnesota.
The IASLC Board of Directors approved a new strategic plan for the organization on September 12, 2011. This ambitious plan was developed after a 6-month process that culminated in a Strategic Planning Retreat, September, 2011 in Denver, USA.
GOAL 1 - IASLC embraces the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies.
GOAL 2 - IASLC provides education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public.
Research and Science
GOAL 3—IASLC advances research and science towards reducing the burden of thoracic malignancies worldwide.
GOAL 4 - IASLC is committed to long-term, global growth in membership.
Professional Membership Association
GOAL 5 - IASLC values the work of its volunteer members, who advance the IASLC mission through active participation and effective leadership.
Charitable Giving and Philanthropic Relationships
GOAL 6 - IASLC solicits philanthropic funds to support its research and educational programs.
GOAL 7 - To accomplish its mission, the IASLC is committed to operational excellence and fiscal responsibility.